MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/neurol-india.neurol-india-d-23-00146

Медицинская библиотека · Neurology India · 2025

Clinicopathological Correlation of TERTp (Telomerase Reverse Transcriptase Promoter) Mutation in Meningiomas.

Nadeem Mohammed, Sravya Palavalasa, Beniwal Manish, Srinivas Dwarakanath, Santosh Vani

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Identifying meningiomas that behave aggressively has proven challenging based on histopathology alone. Several authors have sought to supplement the World Health Organization (WHO) grading system with the use of molecular markers. Although some genetic alterations have been associated with prognosis of patients, it is imperative to validate such markers in different patient cohorts.

OBJECTIVE

To establish the utility of telomerase reverse transcriptase promoter (TERTp) mutation as a prognostic factor in meningiomas.

METHODS

This retrospective study included grade 1 and grade 2 meningiomas in patients aged greater than 18 years operated between 2010 and 2015 at our institute, with a minimum follow-up of 2 years. They were studied for TERTp mutation.

RESULTS

Seventy-one patients fulfilled the above criteria. TERTp mutation was found in five patients (7.04%), while 66 patients had wild-type TERTp. Seventeen patients had recurrence during the follow-up period. All meningiomas with TERTp mutation recurred, while TERTp wild-type meningiomas harbored a 18.2% (12/66) rate of recurrence (P < 0.001). The presence of TERTp mutation was significantly associated with shorter progression-free survival compared to the wild type (28.20 months, versus 93.18 months, P = 0.003).

CONCLUSION

Our report showed a 100% recurrence rate among TERTp mutant meningiomas in a previously unrepresented demographic cohort. This highlights the need for molecular markers as adjuncts to the current WHO grading system, which may help identify meningiomas with aggressive behavior among grade 1 and grade 2 tumors and thus tailor management. Further avenues for research include targeting telomerase for therapeutics.

Для цитирования: Nadeem Mohammed, Sravya Palavalasa, Beniwal Manish, Srinivas Dwarakanath, Santosh Vani. Clinicopathological Correlation of TERTp (Telomerase Reverse Transcriptase Promoter) Mutation in Meningiomas.. Neurology India. 2025. DOI: 10.4103/neurol-india.neurol-india-d-23-00146.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.